1. Home
  2. KRUS vs RLMD Comparison

KRUS vs RLMD Comparison

Compare KRUS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kura Sushi USA Inc.

KRUS

Kura Sushi USA Inc.

HOLD

Current Price

$31.53

Market Cap

485.4M

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$3.27

Market Cap

461.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KRUS
RLMD
Founded
2008
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
485.4M
461.9M
IPO Year
2019
2012

Fundamental Metrics

Financial Performance
Metric
KRUS
RLMD
Price
$31.53
$3.27
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
★ $65.75
$10.75
AVG Volume (30 Days)
197.1K
★ 1.4M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 79.75
45.28
EPS
N/A
★ N/A
Revenue
★ $282,763,000.00
$13,070.00
Revenue This Year
$16.95
N/A
Revenue Next Year
$18.06
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
18.88
★ 154.83
52 Week Low
$33.97
$2.15
52 Week High
$80.84
$8.00

Technical Indicators

Market Signals
Indicator
KRUS
RLMD
Relative Strength Index (RSI) 24.58 39.10
Support Level N/A $3.13
Resistance Level $59.30 $3.55
Average True Range (ATR) 1.67 0.21
MACD -0.56 0.03
Stochastic Oscillator 0.16 39.57

Price Performance

Historical Comparison
KRUS
RLMD

About KRUS Kura Sushi USA Inc.

Kura Sushi USA Inc is a technology-enabled Japanese restaurant concept that provides guests with a distinctive dining experience by serving authentic Japanese cuisine through an engaging revolving sushi service model. The company operates a chain of sushi restaurants across the United States serving freshly prepared Japanese cuisine using high-quality ingredients that are free from artificial seasonings, sweeteners, colorings, and preservatives. The company operates a network of dine-in locations across the U.S. states and Washington, DC.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: